Schr\u00f6dinger, Inc. arrives at its August 5 Q2 earnings with a structural short position that has quietly grown through July — yet the derivatives market remains conspicuously calm.
Short interest has climbed to 16.4% of the free float, up roughly 2% over the past week and holding near the top of its recent range. The ORTEX short score edged to 70.9 during the month, consistent with sustained bearish conviction rather than a sudden tactical bet. Days-to-cover from FINRA data is 9.75, meaning an orderly unwind would take nearly two full trading weeks at normal volumes. The stock itself is down about 7% over the past month, closing at $15.14 on July 31, though it clawed back just over 1% on the week. Yet the borrow market tells a different story entirely. Availability is running at 240% — more than two shares lendable for every one already borrowed — well within the normal range and unchanged in character. Cost to borrow is a negligible 0.44%, down about 8% over the past week. There is no mechanical pressure on shorts here.
Options positioning supports that read. The put/call ratio of 0.56 is almost perfectly in line with its 20-day average of 0.57, with a z-score of just -0.32 — close to the flattest read in recent weeks. Call open interest actually skewed more defensively a fortnight ago; now that has unwound. Structurally, options traders are neither pressing for downside protection nor loading up on upside. The 52-week PCR range spans 0.10 to 0.69, and the current level is stranded in the middle.
The bull-bear divide maps cleanly onto the company's dual identity as both a software platform and a drug developer. Bulls point to the EPS surprise factor score — ranking at the 83rd percentile — and a consensus buy rating with five analysts covering. The mean price target around $20.57 implies roughly 36% upside from current levels, though the most recent analyst action (Morgan Stanley lowering to $17 in May) reflects a Street that has been trimming estimates rather than raising them. Bears focus on the losses: EV/EBITDA is deeply negative at -7.97, the 12-month forward EPS growth factor ranks at just the 3rd percentile, and insiders have been consistent sellers — the CEO sold over $1 million worth of stock in April, and net insider selling over 90 days totalled roughly $539,000 in value.
Ownership adds an interesting wrinkle. The Bill & Melinda Gates Foundation Trust holds 21.6% of shares — a concentrated anchor that limits float — while ARK Investment Management added 73,000 shares as recently as July 31. Both represent conviction-driven holders unlikely to respond to a single quarter's noise, but their presence compresses the actively-traded float further.
Wednesday's print will test whether the computational drug-discovery platform can demonstrate enough commercial pipeline traction to justify the gap between the stock's $15 handle and the analyst community's $20-plus targets — or whether the bears who have been quietly adding to a 16%-of-float position have correctly read where the numbers are heading.
See the live data behind this article on ORTEX.
Open SDGR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
